TELIX Pharmaceuticals Ltd (TLX) - Total Liabilities

Latest as of June 2025: AU$768.01 Million AUD ≈ $543.42 Million USD

Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) has total liabilities worth AU$768.01 Million AUD (≈ $543.42 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

TELIX Pharmaceuticals Ltd - Total Liabilities Trend (2000–2024)

This chart illustrates how TELIX Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. See TLX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

TELIX Pharmaceuticals Ltd Competitors by Total Liabilities

The table below lists competitors of TELIX Pharmaceuticals Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Shift4 Payments Inc NYSE:FOUR	USA	$6.98 Billion
Bains Mer Monaco PA:BAIN	France	€596.51 Million
PPB Group Bhd KLSE:4065	Malaysia	RM1.37 Billion
Sany Heavy Equipment International Holdings Company Limited F:YXS	Germany	€31.75 Billion
Nuvama Wealth NSE:NUVAMA	India	Rs204.64 Billion
Paladin Energy Ltd AU:PDN	Australia	AU$216.44 Million
Predictive Discovery Ltd AU:PDI	Australia	AU$6.91 Million
Premium Brands Holdings Corporation TO:PBH	Canada	CA$5.04 Billion

Liability Composition Analysis (2000–2024)

This chart breaks down TELIX Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TELIX Pharmaceuticals Ltd (TLX) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.82	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.65	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how TELIX Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for TELIX Pharmaceuticals Ltd (2000–2024)

The table below shows the annual total liabilities of TELIX Pharmaceuticals Ltd from 2000 to 2024.

Year	Total Liabilities	Change
2024-12-31	AU$948.22 Million ≈ $670.92 Million	+280.21%
2023-12-31	AU$249.39 Million ≈ $176.46 Million	+39.77%
2022-12-31	AU$178.44 Million ≈ $126.25 Million	+68.06%
2021-12-31	AU$106.17 Million ≈ $75.12 Million	+34.73%
2020-12-31	AU$78.81 Million ≈ $55.76 Million	+147.22%
2019-12-31	AU$31.88 Million ≈ $22.56 Million	+33.92%
2018-12-31	AU$23.80 Million ≈ $16.84 Million	+1221.74%
2017-12-31	AU$1.80 Million ≈ $1.27 Million	+411.63%
2000-12-31	AU$352.00K ≈ $249.06K	--

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$3.28 Billion

AU$4.64 Billion AUD

Market Cap Rank

#4774 Global

#114 in Australia

Share Price

AU$13.85

Change (1 day)

+0.44%

52-Week Range

AU$8.63 - AU$25.75

All Time High

AU$31.14